Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indatuximab ravtansine - Biotest AG

Drug Profile

Indatuximab ravtansine - Biotest AG

Alternative Names: Anti-myeloma monoclonal antibody-DM4 immunoconjugate BT-062; BT-062; Maytansinoid-conjugated anti-myeloma monoclonal antibody BT-062; N2'-Deacetyl-N2'-[4-Methyl-4-(Oxobuthyldithio)-1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal Antibody; nBT062

Latest Information Update: 29 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotest
  • Developer Biotest AG
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Multiple myeloma

Most Recent Events

  • 29 Jan 2018 Indatuximab ravtansine is still at phase II development stage for Bladder cancer and Breast cancer in Germany and Belgium (IV) (Biotest pipeline, January 2018)
  • 29 Jan 2018 Indatuximab ravtansine is still at phase II development stage for Multiple myeloma (Monotherapy, Combination therapy, Second-line therapy or greater) in USA (IV) (Biotest pipeline, January 2018)
  • 04 Aug 2017 Biotest completes a phase I/II trial in Bladder cancer and Breast cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Belgium, Germany (IV) (EudraCT2013-003252-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top